Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gallium-68 PSMA-0057 and Lutetium-177 PSMA-0057 in PSMA-positive mCRPC
CTR20254606Phase 2Active
- Sponsor
- Suzhou Ruihe Pharmaceutical Technology
- Start
- Jun 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of 68Ga-PSMA-0057 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Suzhou Ruihe Pharmaceutical Technology. Started Jun 2026; status: active.
02
Drugs
68Ga-PSMA-0057
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20254606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254606.